Enochian Biosciences Inc. (ENOB) has seen some recent activity in the marketplace and its shares were last quoted at $4.2500 yesterday. Traders are starting to take notice of ENOB as the shares traded as high as $4.3500 and as low as $3.1000 in the prior market trading day.

Enochian Biosciences Inc. (ENOB) average trading volume is 50.24K. However, in the prior market trading day Enochian Biosciences Inc. (ENOB) traded 429,677 shares. The 1st support level on ENOB is $4.18 and the 1st upside resistance level on ENOB is $6.75. ENOB 50-day moving average is $3.4426 and ENOB 200-day moving average is $4.3793.

Enochian Biosciences Inc. (ENOB) most current performance has been specified by the recent movement in ENOB shares. ENOB has performed 10.39% over the past month, ENOB has performed 13.03% over the past quarter and ENOB has shown -27.35% over the past 365 days. Enochian Biosciences Inc. (ENOB) has a 12 month range of $1.9500 to $7.0800. Enochian Biosciences Inc. (ENOB) is trading 117.95% from its 12 month low and -39.97% from its 12 month high. Enochian Biosciences Inc. (ENOB) is indicating a 9.39% short float indicating the quantity short in the float.

ENOB has 40.31M shares outstanding and 14.03M shares in the float. Enochian Biosciences Inc. (ENOB) at this time has a market cap of $171.32M and income of $-3.50M. The market cap of Enochian Biosciences Inc. (ENOB) at $171.32M represents how many Traders own shares of ENOB and is based off the last price ($4.2500) of ENOB and the quantity of shares outstanding (40.31M) with Enochian Biosciences Inc. (ENOB).

Enochian Biosciences Inc. (ENOB) has aggregate cash (mrq) of 8.63M, aggregate cash per share (mrq) of 0.19, aggregate debt of ENOB is at 1.93M and aggregate debt/equity (mrq) is 1.13. Enochian Biosciences Inc. (ENOB) operating cash flow (ttm) is -9.33M and ENOB leveraged free cash flow (ttm) is -6.38M.

ENOB is trading 16.03% above (bullish) its SMA20, 34.86% above (bullish) its SMA50 and -5.78% below (bearish) its SMA200.

Recent News:

In recent news, on May 13, 2020, Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures. In this news it stated, • First presentation of a novel approach to potentially cure HIV  –  An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells   –  A second study provides an in-depth explanation for how the increase in engraftment occurred

About Enochian Biosciences Inc. (ENOB):

Enochian BioSciences Inc. engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of HIV and cancer. The company’s product pipeline consists of ENO-1001, ENO-2001, ENO-3001, ENO-1002, ENO-5001 and ENO-4001.